Physician profile
Janie Yang
NPI 1346668423
$156,146.02
in general payments reported to CMS, 2019-2025
25 companies · $94K in 2025
The $94K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $140 · 2021: $1,278 · 2022: $2,419 · 2023: $9,019 · 2024: $49K · 2025: $94K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $117K · Travel and Lodging: $18K · Food and Beverage: $14K · Consulting Fee: $3,630 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $116,500.00 |
| Travel and Lodging | $18,487.06 |
| Food and Beverage | $13,591.71 |
| Consulting Fee | $3,630.00 |
| Education | $100.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $137,075.09 | 2023-2025 | Omvoh, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $5,083.35 | 2021-2024 | Zeposia, Sotyktu |
| Celgene Corporation | $3,687.28 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,614.52 | 2020-2025 | Xifaxan, Plenvu, Trulance |
| Abbvie INC. | $1,298.46 | 2021-2025 | Viberzi, Linzess, Rinvoq |
| Janssen Biotech, INC. | $1,166.47 | 2021-2025 | Tremfya, Stelara |
| Qol Medical, LLC | $1,124.62 | 2022-2025 | Sucraid, Sucraid |
| Pfizer INC. | $738.58 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $545.09 | 2022-2024 | Dificid |
| Takeda Pharmaceuticals U.S.A., INC. | $501.82 | 2020-2025 | Entyvio, Eohilia |
| Janssen Scientific Affairs, LLC | $446.34 | 2025 | Tremfya |
| Braintree Laboratories, INC. | $352.85 | 2021-2024 | Sutab, Suflave |
| Ironwood Pharmaceuticals, INC | $260.71 | 2020-2024 | Linzess |
| Madrigal Pharmaceuticals | $233.38 | 2025 | Rezdiffra |
| Genzyme Corporation | $210.55 | 2024-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $191.57 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $169.98 | 2024-2025 | Ibsrela |
| Amgen INC. | $156.24 | 2024-2025 | Uplizna |
| Novo Nordisk INC | $122.74 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $53.42 | 2021-2023 | Rebyota |
| Redhill Biopharma INC. | $25.49 | 2020-2021 | |
| Vibrant Gastro, INC. | $25.00 | 2025 | Vibrant Starter Kit |
| Aimmune Therapeutics, INC. | $24.74 | 2025 | Zenpep |
| Endo Pharmaceuticals INC. | $20.73 | 2020 | |
| Phathom Pharmaceuticals, INC. | $17.00 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janie Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.